Onconova Therapeutics Appoints Adar Makovski Silverstein, Ph.D., as Director, Corporate Development
December 13, 2021 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics Announces the Presentation of Preliminary Clinical Data Providing Evidence of Rigosertib’s Activity in RDEB-associated Squamous Cell Carcinoma
December 02, 2021 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 22, 2021 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 11, 2021 16:01 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2021 Financial Results on November 11, 2021
November 04, 2021 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics to Attend the Sachs 21st Annual Biotech in Europe Forum (BEF)
September 29, 2021 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics, Inc. Announces Closing of $21 Million Public Offering of Common Stock
September 28, 2021 16:05 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics, Inc. Announces Pricing of $21 Million Public Offering of Common Stock
September 24, 2021 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
September 23, 2021 16:01 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer
September 22, 2021 08:00 ET
|
Onconova Therapeutics, Inc.
Preliminary Phase 1/2a trial data show an early signal of activity in extensively pre-treated population with 2 partial responses out of 7 evaluable patients Responses were seen in patients with...